RMD:NYE-ResMed Inc. (USD)

EQUITY | Medical Instruments & Supplies | New York Stock Exchange

Last Closing

USD 196.33

Change

+2.15 (+1.11)%

Market Cap

USD 8.15B

Volume

0.57M

Analyst Target

USD 184.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ResMed Inc is a developer, manufacturer and distributor of medical products for treating, diagnosing and managing sleep-disordered breathing and other respiratory disorders.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
BDX Becton Dickinson and Company

N/A

USD 66.90B
ALC Alcon AG

N/A

USD 38.91B
HYB New America High Income Closed..

N/A

USD 35.93B
WST West Pharmaceutical Services I..

N/A

USD 27.24B
BAX Baxter International Inc

N/A

USD 20.44B
TFX Teleflex Incorporated

N/A

USD 10.10B
ATR AptarGroup Inc

N/A

USD 9.48B
STVN Stevanato Group SpA

N/A

USD 7.29B
BLCO Bausch + Lomb Corp

N/A

USD 5.19B
HAE Haemonetics Corporation

N/A

USD 4.30B

ETFs Containing RMD

EDOC:AU BetaShares Digital Health.. 8.94 % 0.00 %

N/A

N/A
EKG First Trust Nasdaq Lux Di.. 8.27 % 0.00 %

N/A

USD 2.33M
EDOC Global X Telemedicine & D.. 5.26 % 0.00 %

N/A

USD 0.05B
EDOC:LSE Global X Telemedicine & D.. 5.05 % 0.00 %

N/A

USD 5.32M
EDOG:LSE Global X Telemedicine & D.. 5.05 % 0.00 %

N/A

USD 5.32M
MCSE Martin Currie Sustainable.. 4.93 % 0.00 %

N/A

USD 0.03B
FDHT 4.59 % 0.00 %

N/A

N/A
FDHT:XETRA Fidelity Digital Health U.. 4.51 % 0.00 %

N/A

USD 4.79M
DDOC:F Global X Telemedicine & D.. 4.29 % 0.00 %

N/A

USD 5.32M
EDOC:SW Global X Telemedicine & D.. 4.29 % 0.00 %

N/A

USD 4.92M
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

N/A

USD 0.05B
MEDTE:PA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

N/A

N/A
MTUSD:PA BNP Paribas Easy ECPI Glo.. 2.23 % 0.00 %

N/A

N/A
PFUT Putnam Sustainable Future.. 2.21 % 0.00 %

N/A

USD 0.23B
HLTH:AU VanEck Global Healthcare .. 2.11 % 0.00 %

N/A

USD 0.06B
EX20:AU BetaShares Australian Ex-.. 1.96 % 0.00 %

N/A

USD 0.27B
RSPH Invesco S&P 500® Equal.. 1.63 % 0.00 %

N/A

USD 1.02B
JKH 0.00 % 0.30 %

N/A

N/A
DDOC:XETRA Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 5.32M
IMCG iShares Morningstar Mid-C.. 0.00 % 0.00 %

N/A

N/A
VCAV:XETRA VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 0.01B
CVGB:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 0.01B
CAVE:LSE VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 0.01B
CAVE:SW VanEck Smart Home Active .. 0.00 % 0.00 %

N/A

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.13% 84% B 86% B+
Dividend Return 0.28% 33% F 14% F
Total Return 14.41% 84% B 85% B
Trailing 12 Months  
Capital Gain -8.05% 32% F 18% F
Dividend Return 0.88% 40% F 9% A-
Total Return -7.17% 32% F 17% F
Trailing 5 Years  
Capital Gain 88.83% 82% B 84% B
Dividend Return 8.05% 88% B+ 28% F
Total Return 96.88% 82% B 83% B
Average Annual (5 Year Horizon)  
Capital Gain 11.36% 65% D 76% C+
Dividend Return 12.24% 65% D 73% C
Total Return 0.88% 55% F 24% F
Risk Return Profile  
Volatility (Standard Deviation) 28.67% 65% D 39% F
Risk Adjusted Return 42.70% 85% B 70% C-
Market Capitalization 8.15B 79% B- 92% A

Key Financial Ratios

  Ratio vs. Industry/Classification (Medical Instruments & Supplies) Ratio vs. Market (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 23.70 81% 25%
Price/Book Ratio 5.73 32% 14%
Price / Cash Flow Ratio 37.04 11% 6%
Price/Free Cash Flow Ratio 18.79 50% 16%
Management Effectiveness  
Return on Equity 21.66% 100% 84%
Return on Invested Capital 19.12% 100% 85%
Return on Assets 11.19% 89% 94%
Debt to Equity Ratio 34.66% 50% 70%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.